Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03313180 · ClinicalTrials.gov registry record · Phase 3
A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 444
- Enrollment target
NCT03313180 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 444 participants.
The verdict
NCT03313180, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 444 participants
- Enrollment target
Study Summary
The main objective is to assess long term safety of treatment with oral nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).
Interventions
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2023-01-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03313180
The ClinicalTrials.gov registry entry for NCT03313180 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nintedanib is the first listed.
NCT03313180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03313180 about?
NCT03313180 is a clinical study titled "A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis". The main objective is to assess long term safety of treatment with oral nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).
What is the current status of trial NCT03313180?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 444 participants. The study started on 2017-11-27. Estimated completion is 2023-01-25.
What interventions are being tested in trial NCT03313180?
The interventions under investigation include: Nintedanib (DRUG).
Who is sponsoring clinical trial NCT03313180?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.